CSF1R and neoplasm: Treatment with agonist anti-CD40 mAbs induced TAM immunostimulatory and tumor inhibitory effects in mouse tumor models both alone and in combination with anti-CSF1R mAb, by enhancing antigen-presentation and pro-inflammatory cytokine production and priming naive T lymphocytes [136,137,138,139].